Velcade sNDA Submitted For Mantle Cell Lymphoma Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Millennium/J&J injection demonstrated a 33% overall response rate among treated patients with the aggressive cancer.
You may also be interested in...
Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.
Agreement provides for two-year co-promotion deal with J&J’s Ortho Biotech subsidiary.
Millennium Inks Velcade Co-Promotion Deal With J&J In U.S.
Agreement provides for two-year co-promotion deal with J&J’s Ortho Biotech subsidiary.
J&J/Millenium Studying Velcade/Rituxan Combo For Treatment Of NHL
Millennium and development partner Johnson & Johnson have initiated a Phase III trial evaluating Velcade (bortezomib) in combination with Genentech/Biogen Idec's Rituxan (rituximab) in the treatment of refractory follicular lymphoma, a subtype of non-Hodgkin's lymphoma, the companies announced April 18
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: